How to Use openFDA and FAERS Data Without Misreading Safety Signals

How to Use openFDA and FAERS Data Without Misreading Safety Signals

This article provides insights on effectively using openFDA and FAERS data while avoiding common pitfalls in interpreting safety signals. It is essential for analysts and business development teams in the pharmaceutical industry. The FDA’s adverse event database has become an indispensable tool for competitive intelligence and regulatory surveillance—but only if you know how to separate signal from noise.

IntelligenceRegulatory Impact▾

FDA and EMA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Key Takeaways

• FAERS is a spontaneous reporting system, not a confirmed causality database; raw case counts alone can mislead even experienced analysts.
• openFDA’s API democratizes access, but proper signal detection requires statistical rigor—disproportionality metrics like the reporting odds ratio (ROR) need context, not blind application.
• Integrating FAERS findings with other data sources (clinical trials, literature, EHR data) and regulatory context is the only way to turn alerts into actionable intelligence for BD and regulatory strategy.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

The Development of FAERS

The FDA Adverse Event Reporting System (FAERS) launched in 2004 as the successor to the legacy Adverse Event Reporting System (AERS). Housed within the Center for Drug Evaluation and Research (CDER), it captures voluntary adverse event reports from healthcare professionals, consumers, and manufacturers—mandatory for license holders. As described in a 2025 Clinical Pharmacology & Therapeutics primer authored by FDA’s Office of Surveillance and Epidemiology, FAERS “is routinely used both for surveillance to identify potential new safety signals and for evaluation of an identified safety signal” (Potter et al., 2025). The database now holds millions of Individual Case Safety Reports (ICSRs), each coded with MedDRA terms.

A real inflection point for external users came in 2015 when the FDA launched openFDA, a developer-friendly API that made FAERS data queryable without bulk downloads. That move turned what was once a niche pharmacovigilance resource into a frontline tool for pharma analysts tracking competitor products or assessing deal targets. Today, openFDA serves up structured weekly updates from FAERS, with endpoints for drugs, reactions, and patient demographics. But as FDA scientists caution in their PMC paper, the database was designed for hypothesis generation, not hypothesis confirmation.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Implications for Pharma BD and Regulatory Teams

For business development and regulatory strategy groups, FAERS is a double-edged sword. Used well, it can reveal emerging safety concerns on a competitor’s asset before they hit a label update, offering a window to reposition a pipeline candidate or reassess deal terms. For instance, a sharp rise in hepatic failure reports for a rival’s kinase inhibitor might derail a licensing negotiation if due diligence uncovers the signal early. Regulatory teams can also mine FAERS to prepare for advisory committee meetings or to contextualize their own product’s safety profile by benchmarking against class-level reporting patterns.

But the competitive value depends entirely on how the data are handled. The European Medicines Agency runs a parallel system—EudraVigilance—and signals that align across both databases carry more weight. Analysts who simply download FAERS cases and present raw counts to their board without adjustment for exposure or confounding often trigger unnecessary alarm or miss true signals buried in noise. BD teams that integrate disciplined FAERS interrogation into their target evaluation process can gain an edge, but those that rely on superficial reports risk costly missteps.

IntelligenceStrategic Takeaways▾

FAERS is a spontaneous reporting system, not a confirmed causality database; raw case counts alone can mislead even experienced analysts. openFDA’s API democratizes access, but proper signal detection requires statistical rigor—disproportionality metrics like the reporting odds ratio (ROR) need context, not blind application. Integrating FAERS findings with other data sources (clinical trials, literature, EHR data) and regulatory context is the only way to turn alerts into actionable intelligence for BD and regulatory strategy.

Common Misinterpretations of Safety Signals

The most frequent error is treating FAERS as a definitive causality register. Reports are submitted voluntarily—aside from manufacturer obligations—and no causal relationship is proven by inclusion. The classic pitfall is the “Weber effect,” where reporting spikes in the first two years after a drug launches, then declines regardless of true risk. Analysts who mistake this natural marketing lifecycle for a safety signal often draw wrong conclusions.

Another misuse: applying disproportionality analysis without clinical plausibility checks. Computing a high ROR for a drug–event pair does not confirm a safety problem; it only flags a statistical association that demands further review. The FDA’s own safety evaluators always combine quantitative filtering with manual case review, looking at temporal plausibility, dechallenge/rechallenge data, and alternative explanations. Overreliance on automated dashboards—especially those that don’t adjust for concomitant medications, underlying disease, or multiple reporting—generates false positives that can distort licensing decisions or investor perceptions.

Denominator neglect is equally damaging. Without reliable usage data, analysts cannot calculate incidence rates. A rise in FAERS cases might reflect expanding patient exposure, not a worsening risk. Some teams attempt to approximate exposure using IQVIA prescriptions or ClinicalTrials.gov enrollment figures, but even those proxies can introduce distortion if not handled carefully.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Best Practices for Using openFDA and FAERS Data

Start with a clear analytical plan. Define the drug(s) of interest, the adverse event terms (MedDRA Preferred Terms), and a comparator set—often all other drugs in the FAERS database as a background. The openFDA API allows retrieval by generic name, brand name, or active moiety, and supports queries for serious outcomes (death, hospitalization, disability). Use disproportionality metrics such as the proportional reporting ratio (PRR) or information component (IC), but always assess them alongside case series narratives obtained via Freedom of Information Act requests when critical.

Cross-validate signals with other pharmacovigilance databases. Check EudraVigilance for the same drug-event combination. Review published case reports, clinical trial safety updates on ClinicalTrials.gov, and even FDA Drug Safety Communications. When a signal persists across multiple data streams, it warrants deeper investigation. Conversely, an isolated FAERS spike with no corroboration often reflects reporting artifact.

Finally, involve a multidisciplinary team. Statisticians can address issues like masking effects in disproportionality calculations; clinicians can evaluate biological plausibility; regulatory experts can weigh the likelihood of FDA action such as a label change or REMS requirement. The FDA’s own guide, published in PMC, stresses that “interpretation of FAERS data requires consideration of the inherent limitations of spontaneous reporting.” Embed that caution into every analysis.

FAQ

Related coverage

• Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications
• Breast Cancer Statistics Worldwide: What the Data Shows
• Obesity rates in America by year: what the data shows